Tuck,
<<So clinically relevant, but not quite as good as LMWH, and compliance is a major issue. Hmmm. What do you think, MZ? I was expecting a bit better.>>
Based on what did you expect better? Data are known for some time and EMIS discontinue this formulation. Actually, it was big mistake to do PIII in first place. Management wasted money, time and source. I mentioned early that technology work (at least for some peptide), but there should be modification and improvement.
So, why I continue to own EMIS? Potential for oral insulin is very big, while inhaled insulin will continue to show problems, imo. In addition, I WANT oral Axokine (but this may be my foolish wish?).
Miljenko |
